advertisement
Abstract #11421 Published in IGR 6-3
Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost
Kaback M; Geanon J; Katz G; Ripkin D; Przydryga JTCurrent Medical Research and Opinion 2004; 20: 1341-1345
OBJECTIVE: To evaluate the efficacy of travoprost 0.004% monotherapy in patients unsuccessfully treated with latanoprost monotherapy. RESEARCH DESIGN AND METHODS: Open-label, noncomparative study conducted at US academic and private practice clinics in adult patients with ocular hypertension or primary open-angle glaucoma who required a change in therapy (due to either inadequate efficacy or safety issues) as judged by the investigator. Intraocular pressure (IOP) was measured at entry and 30 days later. Main outcome measures: Mean change in intraocular pressure (mmHg). RESULTS: Reported here are 488 per-protocol patients from 330 centers who were using latanoprost monotherapy prior to study entry, and who received travoprost monotherapy during the study. Patients had a mean age of 69 years, were approximately two-thirds Caucasian, 60% female, predominantly brown or blue eyes, and 91% were diagnosed as having primary open-angle glaucoma. The mean days in treatment were 31.9 ± 6.4. Mean IOP at study entry was 21.2 mmHg. Following travoprost monotherapy, this was reduced by a mean of 3.2 mmHg to 18 mmHg (p < 0.0001, paired t-test). There were 21 adverse events reported in the intent-to-treat (ITT) population for an incidence of 3.5%. There were some limitations to the current study including: no washout period, no control therapy, single IOP determinations at the beginning and the end of the study; patient compliance with the initial therapy was not measured, and the study was not masked. This study reflects a real-life situation of what a clinician can expect when he changes a patient from latanoprost monotherapy to travoprost monotherapy. CONCLUSION: This study showed that travoprost provided a statistically and clinically significant reduction (p < 0.0001) in IOP of 3.2 mmHg for patients who had not been successfully treated with latanoprost monotherapy. The results of this trial demonstrate the potential benefit of using travoprost as a replacement therapy in order to ensure adequate IOP control.
Dr. J. Przydryga, Alcon Laboratories, 6201 South Freeway, Fort Worth, TX 76134, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
